ERBB2 and neoplasm: Pretreatment tumor characteristics split according to pCR status, indicated that patients with smaller tumors, a positive lymph node prior to treatment initiation, high proliferation, negative ER or PR status, or positive HER2 status were more likely to obtain pCR.